NASA Will Fix Cell Damage for Astronauts and it Could Improve Everyones Healthspan By Ten Years

NASA proposes to pioneer a radically new approach to mitigating radiation-induced cell damage in astronauts by transplanting new undamaged mitochondria (critical radiation-sensitive cell organelles) isolated from each individual pre-exposure.

Replacing mitochondria could fix radiation damage and it can fix aging damage. This would help against cardiovascular disease and Alzheimers. There are early voluntary trials of mitochondria replacement by Mitrix Bio and Biotech Explorers that have started this year.

Researchers in the past decade have found that mitochondria don’t just sit in cells, but in fact constantly transfer around the body. Everyday, hundreds of billions are transferred through the bloodstream, brain, heart, and other organs, in order to supplement cells in need. Many of these mobile mitochondria are encased in extracellular vesicles – what we term “Mitlets.”

Mitlets are a “natural fountain of youth” within the body, used to balance and preserve healthy cellular energetics; an extraordinary evolutionary adaptation to increase survival and longevity of species.

Scaling Mitochondria harvesting and replacement and speeding regulatory approvals is work being done by the Healthspan Action Coalition. Nextbigfuture supports the Healthspan Action Coalition.

Every cell contains hundreds of mitochondria. They are vital organelles tightly integrated into many core cellular processes, and responsible for producing adenosine triphosphate, a chemical energy store molecule used to power the cell. Mitochondria become dysfunctional with age. This is an important contribution to degenerative aging. Cells will readily take up whole mitochondria from the surrounding tissue environment and make use of them. Thus it is possible to introduce large numbers of mitochondria harvested from cell cultures into a tissue in order to largely replace the native mitochondria. Provided that age-related mechanisms of damage and dysfunction that degrade the effectiveness of mitochondrial populations act slowly, then introducing young, functional mitochondria into an old individual should produce a lasting benefit. John G Cramer, a 90-year-old emeritus professor of physics at the University of Washington, has announced he will undergo a novel therapy that uses bioreactor-grown mitochondria, a technology developed by biotech startup Mitrix Bio.

Biotech Explorers, a startup based on research from Stanford and other major universities, is announcing the first-of-their-kind planned human trials of age reversal. These trials target a 130-year human lifespan, or an equivalent age reversal of 30 years, initially for astronauts and people with certain premature aging diseases. Early trials will use bioreactor-grown young mitochondria, transplanted into the body, to restore the decline in mitochondria… a primary cause of age

NASA will investigate this fundamental emerging concept in medicine in the space radiation context, study cell responses to relevant radiation levels, and design a preliminary system to extract, isolate, and shield mitochondria for therapeutic use during travel in deep space. Chronic exposure to deep space radiation remains among the least mitigated threats to long-term human habitation in space, and a large meta-analysis of flight and ground analog experiments has indicated mitochondrial dysfunction as a shared mechanism of spaceflight-induced changes in the body.

Using in vitro human cell models, thet will demonstrate the ability of this targeted mitochondria replacement therapy to restore cellular function after both acute and chronic radiation exposure and assess the dosage and timing required for effective treatment. Using this data, we will create a preliminary system design for using this therapy in flight. This reduction in radiation risk will help safeguard human health in space enabling new classes of longer duration crewed missions such as sustained lunar campaigns, missions to Mars, and even direct human exploration of the outer solar system. Beyond NASA, this technology has the potential to help treat a multitude of age-related degenerative diseases associated with mitochondrial dysfunction such as many cardiovascular diseases and Alzheimer’s disease, improving health for humanity as a whole.

Status of Approved Mitochondrial Replacement and Transplantation Therapies

Mitochondrial replacement/transplantation therapies aim to restore cellular function by introducing healthy mitochondria into damaged cells. There are two primary categories:

Germline Mitochondrial Replacement Therapy (MRT): Used in IVF to prevent inheritance of mitochondrial diseases from the mother. Techniques include pronuclear transfer (PNT) or maternal spindle transfer (MST), creating “three-parent” embryos.

Somatic Mitochondrial Transplantation (MT): Therapeutic infusion of mitochondria (often autologous, from the patient’s own tissues) into affected cells for acquired conditions like ischemia, injury, or disease-related dysfunction. This aligns closely with the NASA proposal, as it targets post-damage repair in adults.

Recent progress (2023–2025) shows advancement in both, with germline MRT achieving regulatory approvals and births, while somatic MT is in clinical trials demonstrating safety but not yet widespread approval.

Below is a summary of key developments, focusing on human trials and approvals.

Approved Treatments

Germline MRT for Inherited Mitochondrial Diseases:Approved in the UK since 2015 (Human Fertilization and Embryology Authority) and Australia since 2022 for preventing severe mitochondrial disorders. It’s restricted to licensed clinics for women carrying pathogenic mitochondrial DNA mutations.

In the UK, a groundbreaking trial (Newcastle Fertility Centre) using PNT resulted in 8 healthy babies born by July 2025, spared from potentially deadly disease.

A July 2025 NEJM study confirmed MRT compatibility with embryo viability, with no adverse effects detected.

Not approved in the US due to FDA restrictions on introducing donor mitochondria (advisory from 2018), though research continues

Safety supported by nonhuman primate studies (2020) showing normal development, fertility, and aging

Other Recent Preclinical/Early Human Advances (2023–2025)

Radiation and Tissue Injury: A 2025 review suggests MT reverses mitochondrial dysfunction in radiation-damaged tissues, amplifying NASA’s work.
Preclinical models show MT reduces oxidative stress from IR exposure.

Vascular/Cardiac: July 2025 study on MT for vascular dysfunction; promising in cardiac IRI, with clinical trials limited but expanding.
Kidney/Neuro: 2025 studies show MT reverses kidney damage and aids spinal cord injury recovery.
Aging/Degenerative: Combined with exercise for muscle atrophy; potential for Alzheimer’s (preclinical).
Osteoarthritis (OA): June 2025 study combining autologous MT with gene therapy (rAAV IGF-I) shows promise for human OA.
Donor-Cell-Free Donation Cardiac Transplant (DCD): July 2025 review explores MT to improve outcomes in heart transplants.
General Reviews: 2025 consensus on nomenclature; biotechnological advances in MT techniques. Trials emphasize autologous sources (e.g., muscle) for safety.

Timeline to Broad Mitochondrial Replacement in Public Health

Anti-aging is mostly not a recognized regulatory endpoint (agencies like FDA require disease-specific outcomes). Timelines depend on trial data, safety profiles, and regional priorities.

Short-Term (2025-2027):

Informal or early-phase trials underway. Mitrix Bio’s volunteer trial (starting August 2025) tests autologous MT in adults over 55 for safety and age-reversal, self-funded and not FDA-regulated as a formal trial.

Minovia’s Phase 2 trial (ongoing as of August 2025) uses placenta-derived mitochondria for mitochondrial diseases, with elderly anti-aging trials planned for 2026 after biomarker development.

Conferences like the Mitochondrial Transplantation Conference (April 2025) and Targeting Mitochondria Congress (October 2025) highlight progress, but no approvals expected soon.

Medium-Term (2028-2032):

Potential Phase 2/3 trials for anti-aging indications if early data shows efficacy (e.g., improved muscle function, cognition). Reviews suggest 5-7 years for standardized guidelines and broader clinical validation.

Approvals could start in progressive regions like Japan or Australia; US/EU might lag due to ethical concerns over three-parent techniques and need for long-term safety data.

Long-Term (2033+):

Widespread approvals if trials confirm benefits for age-related diseases (e.g., Alzheimer’s, sarcopenia). Experts estimate 10+ years for routine use, requiring resolution of challenges like immune responses and delivery efficiency.

System for Harvesting and Scaling Healthy Mitochondria

A blood donation-like system for mitochondria would involve autologous (self-derived) or allogeneic (donor) harvesting, isolation, and banking for broad application. Current methods extract mitochondria from patient tissues (e.g., muscle biopsies or stem cells) or donors (e.g., placenta, which contains “super mitochondria” from young cells).

Scaling requires bioreactors for culturing age-reset mitochondria, storage protocols (e.g., cryopreservation, though activity lasts 1-2 hours on ice), and networks similar to cord blood banks.

Placenta banking (often discarded as waste) could enable donor systems, reducing ethical issues.

Timeline for a Mitochondria Harvesting and Donation System

Short-Term (2025-2027): Proof-of-concept in trials (e.g., Minovia’s placenta-derived MT, Mitrix’s bioreactor-grown autologous MT).

Medium-Term (2028-2032): Pilot banking networks if trials succeed; regulatory frameworks for donation/storage.

Long-Term (2033+): Scaled systems like blood banks, potentially 10-15 years away, needing tech for long-term viability and global standards.

Impact on Healthspan and Lifespan? About 10 Year Healthspan Extension

Mitochondrial dysfunction drives aging via reduced ATP, increased ROS, and cellular damage; MT could reverse this, improving healthspan (years of healthy living) more than lifespan.

Animal studies show enhanced grip strength, endurance, and bioenergy; human trials indicate better energy, physical function, and quality of life in disease models.

Healthspan:

Potential 10-20% improvement by alleviating sarcopenia, neurodegeneration, and metabolic issues. E.g., restored muscle ATP in sarcopenia models; cognitive gains in Alzheimer’s mice.

Could delay onset of age-related diseases, enhancing vitality in elderly.

Lifespan:

Speculative 5-10 year extension if systemic; worm/fly/mouse models show increases via better mito function, but human data limited.

One Mitrix participant speculated living past 122 healthily.